Stock Analysis
Vaxart (NASDAQ:VXRT) Full Year 2022 Results
Key Financial Results
- Net loss: US$107.8m (loss widened by 53% from FY 2021).
- US$0.84 loss per share (further deteriorated from US$0.58 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Vaxart Revenues Disappoint
Revenue missed analyst estimates by 45%. Earnings per share (EPS) was mostly in line with analyst estimates.
Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 3.7% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 5 warning signs for Vaxart (2 can't be ignored!) that you need to be mindful of.
What are the risks and opportunities for Vaxart?
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
Rewards
Trading at 86.2% below our estimate of its fair value
Revenue is forecast to grow 68.19% per year
Risks
Has less than 1 year of cash runway
Makes less than USD$1m in revenue ($107K)
Shareholders have been diluted in the past year
Volatile share price over the past 3 months
Currently unprofitable and not forecast to become profitable over the next 3 years
Further research on
Vaxart
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:VXRT
Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
Good value with adequate balance sheet.
